Sep 21st 2012 - Edison Investment Research today published a report on Ark Therapeutics (AKT.L, LSE:AKT, LON:AKT) entitled "Viral Product Manufacturer". In summary, the report says:
Ark Therapeutics’ transition from a therapeutics development company to a contract development and manufacturing organisation (CDMO) is complete. The near-term investment case therefore rests on its ability to secure contracts for its viral-based cGMP manufacturing facility in Kuopio, Finland. The expertise, capabilities and potential of the Kuopio facility, core to winning over new clients, is firmly established and Ark has a pipeline of 20 potential contracts under discussion with partners ranging from large pharma to academic institutions.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »